AstraZeneca Shares Drop After Reported Merger Talks with Bristol Myers Squibb
AstraZeneca shares fell as much as 7% following reports that the UK-based pharmaceutical giant is in merger discussions with U.S. rival Bristol Myers Squibb, potentially creating a $400 billion healthcare entity. The potential deal has not been confirmed by either company; AstraZeneca declined to comment while Bristol Myers Squibb did not immediately respond outside of regular business hours. The news comes as investors react swiftly to the possibility of one of the largest mergers in the pharmaceutical industry, which could reshape market dynamics and competitive positioning. Such a merger would likely face intense regulatory scrutiny given its scale and impact on global healthcare markets.
